CDK4/6 inhibitors efficiently and accurately inhibit the activity of CDK4/6 kinases in BC cells to block the phosphorylation of retinoblastoma protein, thus blocking the progression of the cell cycle from the G1 to the S phase, in turn inhibiting the proliferation of tumor cells. The gene discussed is CDK4; the disease is neoplasm.